SLC5A2 and heart failure: Interestingly, in preclinical models of anthracycline-induced cardiotoxicity, SGLT2 inhibitor pretreatment significantly reduced heart failure biomarkers, specifically troponins and NT-pro-BNP, while improving cardiac function, thereby demonstrating its cardioprotective properties [27,28,49,50,52,54,55,56,57,58,60,61].